TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03697577

Intervention type: DIAGNOSTIC_TEST
Intervention: CT scans
Description: Patients will undergo CT or PETCT as part of standard of care

Intervention type: DIAGNOSTIC_TEST
Intervention: DEXA scan
Description: Patients will undergo DEXA scan to measure body fat mass (DEXA will be performed only if available)
Study: NCT03367754

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of Placebo given via intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a potent and highly selective humanized monoclonal antibody (immunoglobulin \[Ig\] G4 kappa isotype) that binds to PD-1, thus blocking the receptor from binding with its ligands. Single dose of Pembrolizumab 200 mg given via intravenous (IV) infusion.
Study: NCT01925781

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine polacrilex
Description: 2 mg and 4 mg gum will be used according to the FDA approved product labelling
Study: NCT01087502

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo mach to 5 mg linagliptin first 12 weeks of treatment once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo maching Glimepiride 1-4 mg after 12 weeks of treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo mach to 5 mg linagliptin once daily after 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Description: 5 mg once daily
Study: NCT01925781

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: STAM 1100mAh CE4 eGo Clearomizer
Study: NCT03149900

Intervention type: DRUG
Intervention: Secukinumab
Description: See Arm Description
Study: NCT04038866

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rehabilitation gait with dual task

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: rehabilitation gait without dual task
Study: NCT05438433

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: St.Jude bi leaflet prosthetic mitral valve to replace the diseased valve with preservation of both leaflets
Description: St.Jude prosthetic(FDA approved) mitral valve replacement with or without coronary artery bypass grafts

Intervention type: DEVICE
Group type: OTHER
Intervention: St.Jude bi leaflet prosthetic mitral valve to replace the diseased valve with preservation of both leaflets
Description: St.Jude prosthetic(FDA approved) mitral valve replacement with or without coronary artery bypass grafts
Study: NCT03027713

Intervention type: PROCEDURE
Group type: OTHER
Intervention: weaning protocol
Description: The patients were allocated in the NAVA weaning protocol group o in the PSV weaning protocol group

Intervention type: PROCEDURE
Group type: OTHER
Intervention: weaning protocol
Description: The patients were allocated in the NAVA weaning protocol group o in the PSV weaning protocol group
Study: NCT03470285

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Multiparametric MR imaging (mpMRI)
Description: The main objective of the study is to assess the diagnostic accuracy of mpMRI in small renal tumors. The study characteristics will comply with recommended methods (Quadas, Stard). The population to be included will be representative of patients who would benefit from mpMRI if it is demonstrated to be accurate. In this project, the MR protocol will used the conventional MR sequences either on 1.5 or 3T systems and do not require development. Each center may use their own protocol as long as it includes the mandatory sequences.
Study: NCT03606096

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boostrix IPV infant acellular Pertussis
Description: mother is randomized to receive Boostrix ® Polio (GSK) and infant acellular pertussis

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boostrix IPV infant whole Pertussis
Description: mother is randomized to receive Boostrix ® Polio (GSK) and infant whole Pertussis

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TT infant acellular Pertussis
Description: mother is randomised to receive Tetanus Toxoid and infant acellular Pertussis

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TT infant whole Pertussis
Description: mother is randomised to receive Tetanus Toxoid and infant whole Pertussis
Study: NCT04636697

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intramuscular injection
Description: Subjects will receive two doses of placebo given 21 days apart into the deltoid region of the alternating arm (each arm will be injected once)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intramuscular vaccine
Description: Subjects will receive two doses of 3.75 µg of CoVLP adjuvanted with AS03 adjuvant given 21 days apart into the deltoid region of the alternating arm (each arm will be injected once)
Study: NCT01270763

Intervention type: BEHAVIORAL
Intervention: Intensive lifestyle intervention
Description: Lifestyle intervention focused on weight loss through diet and physical activity

Intervention type: BEHAVIORAL
Intervention: Diabetes support and education
Description: Behavioral intervention focused on diabetes support and education
Study: NCT03427086

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Biotin
Description: High dose biotin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo tablet similar in shape and size to the biotin tablet
Study: NCT00052286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: modafinil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: modafinil
Study: NCT03966911

Intervention type: DEVICE
Group type: OTHER
Intervention: Guardian™ Sensor (3) connected to a Guardian™ Connect Transmitter
Description: Continuous Glucose Monitoring and frequent sample testing
Study: NCT04090021

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole 40mg
Description: Use in a drug combination for H. pylori eradication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40mg
Description: Use in a drug combination for H. pylori eradication

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin 500mg
Description: Use in a drug combination for H. pylori eradication
Study: NCT02249871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: All subjects will be treated for 10 consecutive days including dose escalation, with 5 days on 5 mg oral semaglutide followed by 5 days on 10 mg oral semaglutide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: All subjects will be treated for 10 consecutive days including dose escalation, with 5 days on 5 mg oral semaglutide followed by 5 days on 10 mg oral semaglutide.
Study: NCT04090021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500mg
Description: Use in a drug combination for H. pylori eradication

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole 500 mg
Description: Use in a drug combination for H. pylori eradication

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin 1000 MG
Description: Use in a drug combination for H. pylori eradication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin 1000 MG
Description: Use in a drug combination for H. pylori eradication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin 500mg
Description: Use in a drug combination for H. pylori eradication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifabutin 150 MG
Description: Use in a drug combination for H. pylori eradication
Study: NCT01597791

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Foley catheter
Description: Foley catheter placement after CSE.
Study: NCT02249871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Will be given daily with oral semaglutide.
Study: NCT01628380

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cytoreductive Surgery and HIPEC
Description: CRS: radical surgery, associated to any surgical procedure needed to obtain a zero or ≤ 0.25cm residual tumor (peritonectomy, bowel resection, diaphragmatic stripping, gastric resection, etc.).~HIPEC: Cisplatin (CDDP) (100 mg/m2 of body surface area) + Paclitaxel (175mg/m2 of body surface area). Closed/open technique, as preferred. Duration: 90 minutes. Mean Intra-abdominal Temperature: 42°C.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CRS alone
Description: CRS: radical surgery, associated to any surgical procedure needed to obtain a zero or ≤ 0.25cm residual tumor (peritonectomy, bowel resection, diaphragmatic stripping, gastric resection, etc.)
Study: NCT04123860

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ultrasonic hydrodynamic maxillary sinus lift buccal pad fat
Description: ultrasonic hydrodynamic maxillary sinus lift and buccal fat pad as grafting material followed by immediate implant

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ultrasonic hydrodynamic maxillary sinus lift platelet rich fibrin
Description: ultrasonic hydrodynamic maxillary sinus lift and platelet rich fibrin as grafting material followed by immediate implant
Study: NCT01125774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telcagepant
Description: Telcagepant 140 mg film coated tablet for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match telcagepant 140 mg film coated tablet for oral administration
Study: NCT02005614

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gamma Knife Radiosurgery
Description: Treatment will be administered on an outpatient basis. No other treatment, investigational or commercial agents or therapies other than those described below may be administered with the intent to treat the patient's brain metastases.~Gamma knife radiosurgery is a one day out-patient procedure. Time from initiation of treatment (premedication and placement of a stereotactic frame) until end of treatment (completion of radiation delivery and removal of stereotactic frame) ranges from 3 to 16 hours.
Study: NCT01458275

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclesonide nasal aerosol 37 mcg
Description: ciclesonide nasal aerosol 37mcg - the dose is administered as 1 actuation per nostril to give a total dose of 37 mcg
Study: NCT02434887

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KL029 Intimate Lubricant Gel
Study: NCT03049540

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil 20 MG
Description: Multi-center, double-blind, 1:1 randomized, placebo-controlled clinical trial with Tadalafil

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 20 MG
Description: Multi-center, double-blind, 1:1 randomized, placebo-controlled clinical trial with Tadalafil
Study: NCT04385901

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapy Intervention
Description: Patients receive 2-4 visits (based on patient presentation and need) of physical therapy, up to 4 visits of occupational therapy, up to 4 visits of speech therapy based on need. Treatment focuses on physical strengthening, pulmonary strengthening/breathing exercises, and cognitive rehabilitation.
Study: NCT03176186

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Xenon
Description: 50% xenon by inhalation, delivered by customized xenon delivery system, that includes a ventilator, for the 24h period of TH/TTM. The inhalation therapy is provided in combination with protocol-directed Post-Cardiac Arrest Care dictated by the 2015 guidelines from the American Heart Association and the European Resuscitation Council.
Study: NCT03063385

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parental Communication intervention
Description: In this intervention, we focus on providing parents with basic knowledge about pregnancy, HIV/AIDS, and STDs as a basis for effectively communicating with their adolescents. We work to support attitudes and develop skills to facilitate communication in general and specifically sexual communication. Based on our prior work we focus on prevention beliefs, reaction beliefs, and communication efficacy. Importantly, we include a component on HIV/AIDS stigma as we conceptualize this to impact attitudes and communication about sex. We will program the intervention in such a way so that parents will have to view the Cuídalos program sequentially and in its totality before being able to review any content.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health promotion control condition
Description: In this intervention, we provide a web-based program relying on existing Spanish language web-sites to provide participants with helpful information to prevent significant health problems affecting Puerto Rican adolescents that are related, not to sexual behavior, but to other behaviors. Similar to the experimental condition, we will develop a set of homework related to diet and exercise that we will ask parents to complete with their adolescents.
Study: NCT05113823

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Simulation Training
Description: Simulation Training using High and Low Fidelity Simulator

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Simulation Training
Description: Simulation Training using High and Low Fidelity Simulator
Study: NCT01458275

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ciclesonide nasal aerosol 74 mcg
Description: ciclesonide nasal aerosol 74 mcg - the dose is administered as 1 actuation per nostril to give a total dose of 74 mcg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo - one actuation per nostril
Study: NCT02765243

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-GD2 CART
Description: Anti-GD2 4th Generation Chimeric Antigen Receptor-modified T Cells
Study: NCT04261361

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBCBT intervention
Description: 8 group CBT sessions and 4 weekly follow-up calls

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adherence counseling
Description: All participants in both CBCBT and ETAU groups will have one session of Life-Steps, a stand-alone CBCBT intervention designed to improve adherence to medical recommendations and individualized DM self-management goals.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Adherence counseling
Description: All participants in both CBCBT and ETAU groups will have one session of Life-Steps, a stand-alone CBCBT intervention designed to improve adherence to medical recommendations and individualized DM self-management goals.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psycho-education package
Description: Printed materials of a DM self-management education program will be delivered to both the CBCBT and ETAU groups.
Study: NCT01597791

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No foley catheter
Description: Spontaneous Micturation/ Post Void Residual. the spontaneous micturition algorithm will be assessed for spontaneous micturition and post void residual (PVR) volumes via ultrasonography at regular time intervals.
Study: NCT03002935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPM31510 Oral Nanosuspension 4%
Description: Oral nanosuspension formulation of BPM31510 (ubidecarenone, USP)
Study: NCT04025021

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Targeted Fortification
Description: The TPN and SMOF lipids will be optimized to provide a goal of 4 g/kg/day of protein, and 100-130kcal/kg/day. At 100 ml/kg/day of enteral feeds additional liquid protein and/or microlipids will be added to the breast milk to provide goal of 4 g/kg/day of protein and 100-130 kcal/kg/day. This will be determined by analysis of the milk and reported composition. They will continue targeted fortification for 4 weeks after achieving full feeds of 150 ml/kg/day.
Study: NCT04261361

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psycho-education package
Description: Printed materials of a DM self-management education program will be delivered to both the CBCBT and ETAU groups.
Study: NCT03044496

Intervention type: DRUG
Intervention: Supraclavicular nerve block
Description: Supraclavicular nerve block using ultrasound and 10ml ropivacaine 0.5% with 20ml mepivacaine 1%
Study: NCT03242044

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Congenital diaphragmatic hernia resuscitation with an intact umbilical cord
Description: 10 infants with left or right sided congenital diaphragmatic hernia will be intubated and ventilation initiated while still attached to the placental circulation through the umbilical cord. In addition, at the same time, a nasogastric tube will be placed in the stomach to drain entrained air and secretions. After 5 minutes of resuscitation with the umbilical cord intact, the umbilical cord will be cut, infants separated from the placenta and resuscitation performed per routine neonatal resuscitation protocols. Feasibility, the optimal approach and maternal and infant tolerance to the procedure will be assessed as part of the study.
Study: NCT00429793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temsirolimus
Description: Given IV
Study: NCT01385228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Dose Level Xa - daily administration of pazopanib on days 1 through 21 starting at 400mg with a maximum dose of 1000mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel given IV on Day 1 starting dose 60mg/m2 increase to 75mg/m2
Study: NCT03013361

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Post operative pain control

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Post operative pain control

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Acts as comparator
Study: NCT00147043

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Infusion of stem cells via image guided scan
Study: NCT01866917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5% 20cc injectate bilaterally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04022642

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training
Description: The program will be applied in the first 10-15 minutes of each PE class, twice a week, including a brief warm-up, ranged from 14 to 20 intervals, adopting a 2:1 work to rest ratio (ie, 30-s work, followed by 30-s rest)~A cut-point of \>=90% of maximal heart rate was used as our criterion for satisfactory compliance to high-intensity exercise~In order to estimate effort, fatigue and training load, a subjective effort scale will be used throughout each session. The heart rate will be monitored throughout the session in real time through Bluetooth technology.~Actigraph accelerometers (wGT3X-BT), randomly distributed by the students in each session, will be used to characterize the intensity of the sessions.
Study: NCT02333396

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PICU Supports
Description: The PICU Supports intervention includes navigator activities and ancillary tools. The Navigator activities include: initial visits with the healthcare team members (HTMs) and parents; weekday visits with the parents and feedback to the HTMs as needed; coordination of weekly family meetings between the parents and HTMs; and support during transitions out of the unit. The ancillary tools include: a PICU handbook; a place for parents to keep track of events and their goals; a provider sheet to inform PICU HTMs about important parental issues, concerns or goals; a bedside communication log so parents know which non-PICU HTMs have visited; an end-of-life checklist; a bereavement packet for those whose child dies; and informational resources.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Brochure
Description: Parents will receive a short educational brochure with information about the pediatric intensive care unit.
Study: NCT02427646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BoNT-A
Description: A serotype of botulinum toxins that has specificity for cleavage of SYNAPTOSOMAL-ASSOCIATED PROTEIN 25 (SNAP-25). BoNT-A's pharmacological action is to inhibit the release of acetylcholine from the neuromuscular junction. BoNT-A peripherally applied using optimal parameters by intramuscular injections to treat tremor in the most bothersome upper extremity every 16 weeks over 96 weeks. The study will be extended for those participants who benefited and will receive treatment every 12 weeks over 96 weeks. BoNT-A dose will range from 50-300 U per arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BoNT-A
Description: A serotype of botulinum toxins that has specificity for cleavage of SYNAPTOSOMAL-ASSOCIATED PROTEIN 25 (SNAP-25). BoNT-A's pharmacological action is to inhibit the release of acetylcholine from the neuromuscular junction. BoNT-A peripherally applied using optimal parameters by intramuscular injections to treat tremor in the most bothersome upper extremity every 16 weeks over 96 weeks. The study will be extended for those participants who benefited and will receive treatment every 12 weeks over 96 weeks. BoNT-A dose will range from 50-300 U per arm.
Study: NCT04033224

Intervention type: DEVICE
Intervention: Commercial membrane for Extracorporeal Blood Purification Therapy (EBPT)
Description: Every center will prescribe EBPT with commercial membranes in accordance with local practice and local levels of expertise. No variation in treatment prescription and/or treatment solutions will derive from participation in this prospective observational study. Nonetheless, every setting parameter will be recorded in the web-based registry and analyzed a-posteriori to reveal a potential correlation with the patient outcomes.
Study: NCT04025021

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Miris Human Milk Analyzer
Description: The Miris human milk analyzer is a mid infrared that reports the amount of energy absorbed at each wavelength. The amount of fat (grams), lactose (grams), total protein (grams), true protein (grams), and energy (kcal) per 100 ml will be reported.
Study: NCT04016363

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ProbeFix
Description: ProbeFix vs. manual hold of the ultrasound probe during pharmacological stress-echocardiography examinations